Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
批准号:
6890039
负责人:
RAJ M LAKSHMAN
金额:
$34.82万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2007-04-30
关键词:
alcoholic beverage consumptioncardiovascular disorder preventioncardiovascular disorder riskclinical researchcoronary disorderdrug /alcohol abstinenceenzyme activityenzyme mechanismesterasegenetic polymorphismgenetic susceptibilityhigh density lipoproteinshuman subjectlaboratory ratlow density lipoproteinmacrophagemessenger RNAposttranscriptional RNA processing
中文摘要
描述(由申请人提供):LDL被氧化为氧化LDL(OxLDL),被巨噬细胞迅速摄取,导致冠状动脉疾病(CAD)。对氧磷酶(PON)是HDL结合的多态性酶,降低OxLDL水平,从而预防CAD。PI假设少量饮酒(13-40 g/天)会增加血清PON水平,从而通过阻止OxLDL的形成或破坏OxLDL来降低其水平,从而具有心脏保护作用,而大量饮酒(>80 g/天)则具有相反的作用。PI有以下新数据来支持他的假设:1。与不饮酒者相比,轻度饮酒者的Sewn PON活性增加了3.95倍(p<0.001),但重度饮酒者的活性下降了45%(p<0.001)。2. HDL-PON抑制LDL氧化,这是通过将HDL与抗POP 4或EDTA预先孵育来防止的。3. HDL-PON还能破坏巨噬细胞对OxLDL的摄取,抑制巨噬细胞对OxLDL的摄取。4.与对照组相比,轻度酒精喂养的大鼠肝脏PON mRNA相对于GAPDH mRNA增加了59%(p < 0.001),重度酒精喂养的大鼠肝脏PON mRNA相对于GAPDH mRNA减少了51%(p < 0.001)。因此,PI建议描述酒精对PON和OxLDL状态产生截然相反影响的作用。人类研究:PI将由合格的心脏病专家在戒酒4- 8周之前和之后测定轻度、重度和无肝病的非饮酒者的血清PON活性和蛋白,并与血浆氧化LDI状态和CAD发病率相关。PI将检测每个研究组的血清样本(i)抑制LDL氧化(ii)破坏OxLDL和(iii)防止巨噬细胞摄取OxLDL的能力。PI还将对研究组中的PON基因进行基因分型,以将其与轻度和重度饮酒的易感性相关联。最后,PI将测试轻度或重度饮酒是否上调或下调PON 3等位酶。大鼠研究:由于PON仅在肝脏中表达(PON 3除外),因此只能在明确定义的条件下在动物系统(如大鼠)中研究酒精对POT的分子调节,PI将分别通过B蛋白质印迹和北方印迹分析确定乙醇剂量和暴露持续时间对肝脏PON浓度及其mRNA水平的影响。然后PI将通过核运行和mRNA稳定性试验确定乙醇是否在转录或转录后水平调节PCI mRNA。这些调查可能会导致新的见解,在我们的理解的心脏保护作用的呃饮酒和proatherogenic影响大量饮酒在临床和分子水平。
英文摘要
DESCRIPTION (provided by applicant): LDL is oxidized to oxidized LDL (OxLDL) that is rapidly taken up by macrophages leading to coronary artery disease (CAD). Paraoxonase (PON), a HDL-bound polymorphic enzyme, lowers OxLDL level and thus prevents CAD. The PI hypothesizes that light drinking (13-40 g/day) increases serum PON level and thereby lowers OxLDL by preventing its formation or by destroying it and thus has a cardioprotective effect, whereas heavy drinking (>80 g/day) has the opposite effects. The PI has the following new data to support his hypothesis: 1. Sewn PON activity is increased 3.95-fold (p<0.0O1) in light drinkers, but decreased by 45 percent (p<0.001) in heavy drinkers compared to nondrinkers. 2. HDL-PON inhibited LDL oxidation that is prevented by prior incubation of HDL with either anti-POP4 or EDTA. 3. HDL-PON also destroyed OxLDL and inhibited OxLDL uptake by macrophages. 4. Hepatic PON mRNA relative to GAPDH mRNA is increased by 59 percent (p < 0.001) in light alcohol-fed and decreased by 51 percent (p < 0.001) in heavy alcohol-fed rats compared to controls. Therefore, the PI proposes to delineate the action of alcohol in causing diametrically opposite effects on PON and OxLDL status. Studies in humans: The PI will determine serum PON activity and protein in light, heavy and non-drinker without liver disease before and after 4- & 8-week abstinence and correlate with plasma oxidized LDI status and incidence of CAD by qualified cardiologists. The PI will test serum samples from each study group for their ability to (i) inhibit LDL oxidation (ii) destroy OxLDL and (iii) prevent OxLDL uptake by macrophages. The PI will also genotype PON genes in the study groups to correlate their susceptibility to light and heavy alcohol drinking. Finally, the PI will test whether light or heavy drinking up-regulated or down-regulates PON3 allozyme. Studies in rats: Since PON is expressed only in the liver (except PON3), molecular regulation of POT by alcohol can only be studied in an animal system like rat under well-defined conditions, the PI will determine the effects of ethanol dosage and duration of exposure on hepatic PON concentration and its mRNA level b Western Blot and Northern Blot analyses, respectively. The PI will then determine whether ethanol regulates PCI mRNA at transcriptional or post-transcriptional level by Nuclear-run-on and mRNA stability assays. These investigations are likely to lead to new insights in our understanding of the cardioprotective effects of Ugh drinking and proatherogenic effects of heavy drinking both at clinical and at molecular levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANTI INFLAMMATORY AND ANTIFIBROTIC ACTIONS OF THYMOSIN BETA 4 IN ALD
-
批准号:8854003
-
项目类别:
-
资助金额:$17.57万
-
财政年份:2014
-
负责人:RAJ M LAKSHMAN
-
依托单位:
ANTI INFLAMMATORY AND ANTIFIBROTIC ACTIONS OF THYMOSIN BETA 4 IN ALD
-
批准号:8609964
-
项目类别:
-
资助金额:$14.96万
-
财政年份:2014
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Novel Modulators of Alcohol Induced Metabolic and Liver Injury
-
批准号:8724156
-
项目类别:
-
资助金额:$10.6万
-
财政年份:2013
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8307287
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8504896
-
项目类别:
-
资助金额:$27.83万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8702054
-
项目类别:
-
资助金额:$39.31万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8460995
-
项目类别:
-
资助金额:$3.15万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8203160
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
NOVEL MODULATORS OF ALCOHOL INDUCED METABOLIC AND LIVER INJURY
-
批准号:8900880
-
项目类别:
-
资助金额:$45.4万
-
财政年份:2011
-
负责人:RAJ M LAKSHMAN
-
依托单位:
BRAIN SOCS3 AND PTP1B-ADIPOSE LEPTIN FEEDBACK AXIS IN ALCOHOLIC HEPATOSTEATOSIS
-
批准号:8144479
-
项目类别:
-
资助金额:$15.14万
-
财政年份:2010
-
负责人:RAJ M LAKSHMAN
-
依托单位:
BRAIN SOCS3 AND PTP1B-ADIPOSE LEPTIN FEEDBACK AXIS IN ALCOHOLIC HEPATOSTEATOSIS
-
批准号:8065693
-
项目类别:
-
资助金额:$18.9万
-
财政年份:2010
-
负责人:RAJ M LAKSHMAN
-
依托单位:
MODULATORS OF ALCOHOLIC LIPIDEMIA & STEATOSIS:KEY ROLE OF SCAVENGER RECEPTOR B I
-
批准号:7926902
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2009
-
负责人:RAJ M LAKSHMAN
-
依托单位:
ACTION OF ALCOHOL/QUERCETIN ON ANTI-ATHEROGENIC FACTOR
-
批准号:7146990
-
项目类别:
-
资助金额:$18.11万
-
财政年份:2006
-
负责人:RAJ M LAKSHMAN
-
依托单位:
ACTION OF ALCOHOL & QUERCETIN ON ANTI-ATHEROGENIC FACTORS & ATHEROGENESIS
-
批准号:7267983
-
项目类别:
-
资助金额:$17.59万
-
财政年份:2006
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:6542331
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:6917377
-
项目类别:
-
资助金额:$6.28万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:6744843
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:7623633
-
项目类别:
-
资助金额:$3.15万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:7057373
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位:
Light & Heavy Alcohol, Paraoxonase & Oxidized LDL Status
-
批准号:6604221
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2002
-
负责人:RAJ M LAKSHMAN
-
依托单位: